PaTHway Adolescent - A Phase 3, Multicenter, Open-Label Single-Arm Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Palopegteriparatide Administered Subcutaneously Daily in the Adolescent Population (12 Years to Less Than 18 Years of Age) with Chronic Hypoparathyroidism
Yorvipath 420 micrograms/1.4 mL solution for injection in pre‑filled penYorvipath 168 micrograms/0.56 mL solution for injection in pre-filled penYorvipath 294 micrograms/0.98 mL solution for injection in pre‑filled pen
Eligibility
Age group
0-17 years
Sex
Female, Male
Primary endpoint
At Week 26, proportion of participants with: Albumin-adjusted serum calcium within the normal range measured within 4 weeks prior to and on the Week 26 visit; and, Independence from active vitamin D and, Independence from therapeutic doses of calcium. Calcium ≤600 mg/day (in the form of tablets, powder, liquid suspension, or transdermal patch) is considered as “supplemental” to meet recommended daily intake for general health, as opposed to a “therapeutic” dose to treat hypoparathyroidism
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.